What to do until the POEMs arrive: An endothelial example

Journal of Family Practice

Volumn 49, Issue 4, 2000, Pages 362-368

  Ganiats, Theodore G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PATHWAY; ENDOTHELIUM; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; HUMAN; MEDICAL DECISION MAKING;

CRITICAL PATHWAYS; DECISION MAKING; ENDOTHELIUM, VASCULAR; FAMILY PRACTICE; HUMANS;

EID: 0033931645     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hawkey CJ, Karrasch JA, Szczepaanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: omeprazole versus misoprostol for NSAID-induced ulcer management. OMNIUM Study Group. N Engl J Med 1998; 338:727-34.
2. Yeomans ND, Tulassay Juhaasz L, Raacz, I, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment. ASTRONAUT Study Group. N Engl J Med 1998; 338:719-26.
3. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44-51.
4. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989; 79:441-4.
5. Pfeffer MA, Braunwald E. Ventricular remodeling following myocardial infarction: experimental observations and clinical implications. Circulation 1990; 81:1161-72.
6. Boyle MH, Torrance GW, Sinclair JC, et al. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med 1983; 308:1330-7.
7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643-50.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinvian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
9. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97:1446-52.
10. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-22.
11. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-5.
12. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993; 87(suppl V):V56-66.
13. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21:1145-51.
14. Egashira K, Kirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion patients with hypercholesterolemia. Circulation 1994; 89:2519-24.
15. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669-77.
16. Drexler H, Kurz S, Jeserich M, et al. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995; 76:13E-18E.
17. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-65.
18. Pepine CJ, Drexler H, Dzau VJ, eds. Endothelial function in cardiovascular health and disease. New York, NY: Landmark Programs for the University of Florida; 1997.
19. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22(suppl 4):S1-14.
20. Brooke TA, Capasso EA. Thrombin and histamine activate phospholipase C in human endothelial cells via a phorbol ester-sensitive pathway. J Cell Physiol 1988; 136:54-62.
21. Nollert MU, Eskin SG, McIntire LV. Shear stress increases inositol triphosphate levels in human endothelial cells. Biochem Hiophys Res Commun 1990; 170:281-7.
22. Cooke JP, Rossitch E, Andon NA, et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88:1663-71.
23. 2+) coupling in vascular endothelial cells. Am J Physiol 1991; 261:H149-54.
24. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite. The basis for the proposal that the acid-activatible inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, ed. Mechanisms of vasodilation. New York, NY: Raven Press; 1988:401-14.
25. Rubanyi GM, ed. Cardiovascular significance of endothelium-derived vasoactive factors. Mount Kisco, NY: Futura; 1991:1-357.
26. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38:87-104.
27. Vanhoutte PM, Auch-Schwelk W, Biondi MI, et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol 1989; 28:95S-104S.
28. Feletou M, Teisseire B. Converting enzyme inhibition in isolated procine resistance artery potentiates bradykinin relaxation. Eur J Pharmacol 1990; 190:159-66.
29. Boglie RG, Coade SB, Moncada S, et al. Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 1991; 180:926-32.
30. Cooke JP, Stamler J, Andon N, et al. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990; 259:H804-12.
31. Glover RP, Davila JC, Kyle RH, et al. Ligation of the internal mammary arteries as a means of increasing blood supply to the myocardium. J Thorac Surg 1957; 34:661-73.
32. Gorlin R. Revascularization of the myocardium. In: Gorlin R. Coronary artery disease. Philadelphia, Pa: WB Saunders Co; 1976:263-87.
33. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971; 215:1777-85.
34. Miller AB. Breast cancer screening: who should be included? J Gen Int Med 1990; 5:S19-22.
35. Prorok PC, Byar DP, Smart CR, et al. Evaluation of screening for prostate, lung, and colorectal cancers: the PLC trial. In: Miller AB, Chamberlain J, Day NE, et al, eds. Cancer screening. Cambridge, Mass: Cambridge Univ Press; 1991.
36. American Cancer Society. Guidelines for the cancer-related check-up: recommendations and rationale. 1980; 30:193-240.
37. Miller AB, Chamberlain J, Day NE, et al. Report on a workshop of the UICC project on evaluation of screening for cancer. Int J Cancer 1990; 46:761-9.
38. Lusher TF, Tanner FC, Tschudi MR, et al. Endothelial dysfunction in coronary artery disease. Annu Rev Med 1993; 44:395-418.
39. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-8.
40. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-63.